Evaluation of Anxiety Levels in Patients Undergoing Intravitreal Injections and Associated Risk Factors Related to the Disease

Table 3

Final fitted multivariate regression model.

Variable	Coefficient	value
Age (decades)	−4.20	0.036
Sex (female)	+11.87	0.013
Anti-VEGF
Bevacizumab	Reference
Ranibizumab	−9.03	0.136
Aflibercept	−11.88	0.097
Improvement in binocular BCVA	+24.94	0.141

Adjusted R² = 0.10. BCVA, best-corrected visual acuity.